Geron Announces FDA Approval of RYTELO™ (imetelstat),

Geron Announces FDA Approval of RYTELO™ (imetelstat), a First-in-Class Telomerase Inhibitor, for the Treatment of Adult Patients with Lower-Risk MDS with Transfusion-Dependent Anemia

Approval across ESA ineligible and ESA relapsed/refractory patients with LR-MDS with transfusion-dependent anemia, regardless of ring sideroblast status

Durable and sustained red blood cell...

Related Keywords

Johna Scarlett , , Linkedin , Drug Administration , Exchange Commission , Geron Corporation Nasdaq , Malignant Hematology Department , Moffitt Cancer Center , Patient Support Program , Geron Corporation , Chief Executive , Rami Komrokji , Vice Chair , Conference Call , Eastern Time , Prescribing Information , Medication Guide , Private Securities Litigation Reform Act , Myelodysplastic Syndromes , Emerging Therapeutic , Cancer Manag ,